NextCure (NXTC) Stock Price, News & Analysis

+0.01 (+0.63%)
(As of 04/22/2024 ET)
Today's Range
50-Day Range
52-Week Range
101,385 shs
Average Volume
237,039 shs
Market Capitalization
$44.92 million
P/E Ratio
Dividend Yield
Price Target

NextCure MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
272.7% Upside
$6.00 Price Target
Short Interest
4.71% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
Insider Trading
Proj. Earnings Growth
From ($1.65) to ($1.62) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.90 out of 5 stars

Medical Sector

194th out of 909 stocks

Pharmaceutical Preparations Industry

74th out of 423 stocks

NXTC stock logo

About NextCure Stock (NASDAQ:NXTC)

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

NXTC Stock Price History

NXTC Stock News Headlines

[Shocking] Elon Musk’s Plan To End Banks
Leaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030.
Will NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?
[Shocking] Elon Musk’s Plan To End Banks
Leaked Elon Musk call reveals shocking plan to replace banks. As Musk's plan rolls out, industry experts predict it could spark a wave of mass crypto adoption. Triggering a new crypto bull run. While helping drive a booming crypto asset class up from $2.5-billion to $16-trillion (a 6,400x increase) by 2030.
NextCure Provides Year-End Clinical Pipeline Updates
NextCure Inc NXTC
See More Headlines
Receive NXTC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NextCure and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
2 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$4.10 per share


Free Float
Market Cap
$44.92 million
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Michael S. Richman MSBA (Age 63)
    Co-Founder, CEO, President & Director
    Comp: $713.95k
  • Dr. Solomon Langermann Ph.D. (Age 64)
    Chief Scientific Officer
    Comp: $538.62k
  • Dr. Han Myint FACP (Age 71)
    M.D., Chief Medical Officer
    Comp: $554.46k
  • Dr. Lieping Chen M.D. (Age 67)
    Ph.D., Co-Founder & Chairman of Scientific Advisory Board
  • Mr. Steven P. Cobourn CPA (Age 61)
    Chief Financial Officer
    Comp: $313.25k
  • Dr. Timothy Mayer Ph.D. (Age 59)
    Chief Operating Officer
  • Mr. Kevin G. Shaw (Age 50)
    General Counsel
  • Ms. Stacy Rollinger
    Vice President of Human Resources
  • Mr. Sourav Kundu Ph.D. (Age 64)
    Senior Vice President of Development & Manufacturing
  • Dr. Sebastien Maloveste
    Senior Vice President of Business Development

NXTC Stock Analysis - Frequently Asked Questions

Should I buy or sell NextCure stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NextCure in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NXTC shares.
View NXTC analyst ratings
or view top-rated stocks.

What is NextCure's stock price target for 2024?

2 brokers have issued 1-year target prices for NextCure's shares. Their NXTC share price targets range from $4.00 to $8.00. On average, they predict the company's share price to reach $6.00 in the next twelve months. This suggests a possible upside of 272.7% from the stock's current price.
View analysts price targets for NXTC
or view top-rated stocks among Wall Street analysts.

How have NXTC shares performed in 2024?

NextCure's stock was trading at $1.14 at the start of the year. Since then, NXTC shares have increased by 41.2% and is now trading at $1.61.
View the best growth stocks for 2024 here

When is NextCure's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our NXTC earnings forecast

How were NextCure's earnings last quarter?

NextCure, Inc. (NASDAQ:NXTC) announced its quarterly earnings results on Thursday, March, 21st. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.54) by $0.02.

What other stocks do shareholders of NextCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NextCure investors own include SCYNEXIS (SCYX), ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Novan (NOVN), Organigram (OGI), Kadmon (KDMN), Sorrento Therapeutics (SRNE), Vaxart (VXRT) and DHT (DHT).

When did NextCure IPO?

NextCure (NXTC) raised $75 million in an IPO on Thursday, May 9th 2019. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofAMerrill Lynch, Pierce and Piper Jaffray served as the underwriters for the IPO.

How do I buy shares of NextCure?

Shares of NXTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:NXTC) was last updated on 4/23/2024 by Staff

From Our Partners